T Konno1,2, K Yoshida3, I Mizuta4, T Mizuno4, T Kawarai5, M Tada2, H Nozaki6, S-I Ikeda7, O Onodera2, Z K Wszolek1, T Ikeuchi8. 1. Department of Neurology, Mayo Clinic, Jacksonville, FL, USA. 2. Department of Neurology, Brain Research Institute, Niigata University, Niigata, Japan. 3. Department of Brain Disease Research, Shinshu University School of Medicine, Matsumoto, Nagano, Japan. 4. Department of Neurology, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kyoto, Japan. 5. Department of Clinical Neuroscience, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan. 6. Department of Medical Technology, School of Health Sciences Faculty of Medicine, Niigata University, Niigata, Japan. 7. Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Nagano, Japan. 8. Department of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan.
Abstract
BACKGROUND AND PURPOSE: To establish and validate diagnostic criteria for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) due to colony-stimulating factor 1 receptor (CSF1R) mutation. METHODS: We developed diagnostic criteria for ALSP based on a recent analysis of the clinical characteristics of ALSP. These criteria provide 'probable' and 'possible' designations for patients who do not have a genetic diagnosis. To verify its sensitivity and specificity, we retrospectively applied our criteria to 83 ALSP cases who had CSF1R mutations (24 of these were analyzed at our institutions and the others were identified from the literature), 53 cases who had CSF1R mutation-negative leukoencephalopathies and 32 cases who had cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) with NOTCH3 mutations. RESULTS: Among the CSF1R mutation-positive cases, 50 cases (60%) were diagnosed as 'probable' and 32 (39%) were diagnosed as 'possible,' leading to a sensitivity of 99% if calculated as a ratio of the combined number of cases who fulfilled 'probable' or 'possible' to the total number of cases. With regard to specificity, 22 cases (42%) with mutation-negative leukoencephalopathies and 28 (88%) with CADASIL were correctly excluded using these criteria. CONCLUSIONS: These diagnostic criteria are very sensitive for diagnosing ALSP with sufficient specificity for differentiation from CADASIL and moderate specificity for other leukoencephalopathies. Our results suggest that these criteria are useful for the clinical diagnosis of ALSP.
BACKGROUND AND PURPOSE: To establish and validate diagnostic criteria for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) due to colony-stimulating factor 1 receptor (CSF1R) mutation. METHODS: We developed diagnostic criteria for ALSP based on a recent analysis of the clinical characteristics of ALSP. These criteria provide 'probable' and 'possible' designations for patients who do not have a genetic diagnosis. To verify its sensitivity and specificity, we retrospectively applied our criteria to 83 ALSP cases who had CSF1R mutations (24 of these were analyzed at our institutions and the others were identified from the literature), 53 cases who had CSF1R mutation-negative leukoencephalopathies and 32 cases who had cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) with NOTCH3 mutations. RESULTS: Among the CSF1R mutation-positive cases, 50 cases (60%) were diagnosed as 'probable' and 32 (39%) were diagnosed as 'possible,' leading to a sensitivity of 99% if calculated as a ratio of the combined number of cases who fulfilled 'probable' or 'possible' to the total number of cases. With regard to specificity, 22 cases (42%) with mutation-negative leukoencephalopathies and 28 (88%) with CADASIL were correctly excluded using these criteria. CONCLUSIONS: These diagnostic criteria are very sensitive for diagnosing ALSP with sufficient specificity for differentiation from CADASIL and moderate specificity for other leukoencephalopathies. Our results suggest that these criteria are useful for the clinical diagnosis of ALSP.
Authors: T Konno; D F Broderick; N Mezaki; A Isami; D Kaneda; Y Tashiro; T Tokutake; B M Keegan; B K Woodruff; T Miura; H Nozaki; M Nishizawa; O Onodera; Z K Wszolek; T Ikeuchi Journal: AJNR Am J Neuroradiol Date: 2016-09-15 Impact factor: 3.825
Authors: Alexandra Götz; Henna Tyynismaa; Liliya Euro; Pekka Ellonen; Tuulia Hyötyläinen; Tiina Ojala; Riikka H Hämäläinen; Johanna Tommiska; Taneli Raivio; Matej Oresic; Riitta Karikoski; Outi Tammela; Kalle O J Simola; Anders Paetau; Tiina Tyni; Anu Suomalainen Journal: Am J Hum Genet Date: 2011-05-05 Impact factor: 11.025
Authors: Christina Sundal; Jay A Van Gerpen; Alexandra M Nicholson; Christian Wider; Elizabeth A Shuster; Jan Aasly; Salvatore Spina; Bernardino Ghetti; Sigrun Roeber; James Garbern; Anne Borjesson-Hanson; Alex Tselis; Russell H Swerdlow; Bradley B Miller; Shinsuke Fujioka; Michael G Heckman; Ryan J Uitti; Keith A Josephs; Matt Baker; Oluf Andersen; Rosa Rademakers; Dennis W Dickson; Daniel Broderick; Zbigniew K Wszolek Journal: Neurology Date: 2012-07-25 Impact factor: 9.910
Authors: Alexandra M Nicholson; Matt C Baker; Nicole A Finch; Nicola J Rutherford; Christian Wider; Neill R Graff-Radford; Peter T Nelson; H Brent Clark; Zbigniew K Wszolek; Dennis W Dickson; David S Knopman; Rosa Rademakers Journal: Neurology Date: 2013-02-13 Impact factor: 9.910
Authors: R M Ahmed; E Murphy; I Davagnanam; M Parton; J M Schott; C J Mummery; J D Rohrer; R H Lachmann; H Houlden; N C Fox; J Chataway Journal: J Neurol Neurosurg Psychiatry Date: 2013-12-19 Impact factor: 10.154
Authors: David S Lynch; Wei Jia Zhang; Rahul Lakshmanan; Justin A Kinsella; Günes Altiokka Uzun; Merih Karbay; Zeynep Tüfekçioglu; Hasmet Hanagasi; Georgina Burke; Nicola Foulds; Simon R Hammans; Anupam Bhattacharjee; Heather Wilson; Matthew Adams; Mark Walker; James A R Nicoll; Jeremy Chataway; Nick Fox; Indran Davagnanam; Rahul Phadke; Henry Houlden Journal: JAMA Neurol Date: 2016-12-01 Impact factor: 18.302
Authors: T Konno; K Yoshida; T Mizuno; T Kawarai; M Tada; H Nozaki; S-I Ikeda; M Nishizawa; O Onodera; Z K Wszolek; T Ikeuchi Journal: Eur J Neurol Date: 2016-09-29 Impact factor: 6.089
Authors: T Konno; T Miura; A M Harriott; N Mezaki; E S Edwards; R Rademakers; O A Ross; J F Meschia; T Ikeuchi; Z K Wszolek Journal: Eur J Neurol Date: 2018-04-03 Impact factor: 6.089
Authors: Adit Friedberg; Eliana Marisa Ramos; Zhongan Yang; Luke W Bonham; Jennifer S Yokoyama; Peter A Ljubenkov; Kyan Younes; Daniel H Geschwind; Bruce L Miller Journal: Front Neurol Date: 2022-06-22 Impact factor: 4.086